6533b830fe1ef96bd1297bc9

RESEARCH PRODUCT

Phase 2 Trial of the Continuous IV Administration of Interferon-? in Patients With Disseminated Malignant Melanoma

Susanne Voelter-mahlknechtUlrich MahlknechtGerhard FierlbeckStephan Letzel

subject

MaleOncologymedicine.medical_specialtySkin NeoplasmsAngiogenesisAntineoplastic AgentsDrug Administration ScheduleInterferonInternal medicinemedicineHumansIn patientNeoplasm MetastasisInfusions IntravenousMelanomaAgedInterferon betabusiness.industryMelanomaInterferon-betaGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyDiscontinuationSurgeryTreatment OutcomeToxicityFemalebusinessmedicine.drug

description

BACKGROUND Interferons have been reported to significantly contribute to tumor suppression via both induction of p53 gene expression and inhibition of angiogenesis. OBJECTIVE The assessment of treatment toxicity and antitumoral effectiveness of continuous IV administration of interferon-beta based on an overall evaluation of laboratory, radiographic, and clinical parameters observed during the trial. METHODS The authors treated patients with advanced malignant melanoma with continuous IV infusions of 1 x 10(6) IU interferon-beta daily ( approximately 0.6 x 10(6) IU interferon-beta/m2 daily). RESULTS Continuous IV administration of interferon-beta had no significant effect on overall patient outcome. Interferon side effects were not a reason for treatment discontinuation in any of the patients observed during this trial. CONCLUSIONS Continuous IV interferon-beta had no significant effect on overall patient outcome in a group of patients with advanced malignant melanoma. To our knowledge, this is the first report on the continuous IV administration of interferon-beta in patients with advanced malignant melanoma.

yearjournalcountryeditionlanguage
2006-11-07SKINmed
https://doi.org/10.1111/j.1540-9740.2006.05678.x